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Iron is an essential nutrient, and disorders of iron metabolism are common.
Nonetheless, intestinal iron absorption and cellular iron transport are poorly
understood. Biochemical approaches to elucidating these processes have yield-
ed little in the past decade. As an alternative approach, we have begun to study
spontaneous mouse mutants, that have inherited defects in key steps in iron
transport. We have undertaken positional cloning of the gene responsible for
microcytic anemia (gene symbol mk). This report describes the important char-
acteristics of these mice, and our progress in studying them.
INTRODUCTION
Iron is an essential nutrient, that is required by all organisms for basic cellular func-
tions including oxidative metabolism and DNA synthesis. Vertebrates also require iron as
a component ofthe oxygen carrying molecule, hemoglobin. While it is necessary for life,
iron is invariably toxic in excess. Hence, its absorption must be strictly regulated. Iron
deficiency is manifest primarily by anemia resulting from insufficiency ofiron for hemo-
globin production. Iron deficiency anemia affects an estimated 600 million individuals
worldwide, primarily women and young children. While iron deficiency anemia is most
often due to dietary insufficiency, an interesting subset of patients have inherited defects
in iron transport.
At the other extreme, hemochromatosis is a disease of iron accumulation, resulting
from inappropriately increased absorption ofdietary iron. There are two prevalent genet-
ic forms of hemochromatosis. Hereditary hemochromatosis is the most common genetic
disease ofindividuals ofNorthern European descent. Approximately one in ten individu-
als in that population carry at least one copy of a mutant gene, dubbed HFE [1].
Heterozygotes have subclinical iron loading, and untreated homozygotes accumulate up
to ten times normal body iron stores by middle age. Without intervention, iron toxicity
leads to failure ofthe liver, heart and endocrine organs.
African iron overload affects many individuals in the sub-Saharan portion of the
African continent. This disease is similar to hereditary hemochromatosis, though the pat-
tern of iron deposition differs slightly. African iron overload appears to have a genetic
basis [2], but it is unlinked to HFE, and the responsible gene has not been mapped.
Despite the prevalence and severity of these disorders, iron transport remains poorly
understood. Figure 1 summarizes the important iron compartments in mammals. Dietary
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Figure 1. Iron compartments. At the top, arrows indicate the entry of iron into, and exit of iron
from the body. Filled circles represent the major iron compartments within the body - storage iron
(primarily hepatic ferritin), transit iron (diferric transferrin circulating in plasma) and actively used
iron (in the form of hemoglobin, in the erythron). Question marks (?) indicate that little is known
about most transport steps. Tf = transfernin.
iron enters the body through the intestinal epithelium. The mechanisms by which iron
enters, transits and leaves the enterocyte are unknown. Several models have been pro-
ppsed, but none has met with widespread acceptance, and they will not be discussed here.
There is no physiologic mechanism for the excretion ofiron in mammals; iron leaves the
body through sloughing of mucosal cells and loss of blood. Iron balance is regulated,
therefore, strictly at the level ofabsorption. Women absorb more iron than men, to com-
pensate for regular menstrual blood loss.
On the serosal side of the enterocyte iron is quickly bound to the chelator protein,
transferrin, to enter the transit compartment. Chelation detoxifies iron by making it less
reactive. Diferric transferrin delivers iron to the storage compartment, which primarily
consists ofhepatic ferritin, and to the major sites ofuse, most notably the erythroid bone
marrow. Little is known of how iron enters or leaves hepatic cells, though it is clear that
it must be removed from transferrin, and it must remain in an exchangeable form.
Iron entry into the erythron is partially explained by an endocytotic process termed
the transferrin cycle. Diferric transferrin binds to specific receptors on the surface ofery-
throid precursors, and the ligand-receptor complex is endocytosed to form specific endo-
somes. Next, endosomes are acidified through the action ofaproton pump, leading to iron
release. These steps have been elegantly described by Klausner, Lodish and theirco-work-
ers [reviewed in 3]. Apotransferrin and transferrin receptors are recycled back to the cell
surface to repeat thecycle. The fate ofthe iron, however, is notwell understood. Somehow
iron must transit the lipid bilayer surrounding the endosome, to gain access to the cyto-
plasm and ultimately to the mitochondrion where it is incorporated into heme.
We would like to identify the molecules which transport iron across the membranes
of the intestinal cell and the red cell. To do this, we have taken a novel genetic approach.
The power of this approach becomes apparent from analysis of a patient, and a mutant
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mouse, which have identical phenotypes due to defects in iron transport. The patient will
be presented briefly, and the mouse model will be discussed in detail.
IRON-RESISTANT IRON DEFICIENCY ANEMIA IN A TODDLER
P.D. was referred to our center for evaluation of "iron-resistant iron deficiency ane-
mia." He was the 4.3 kg product of a healthy mother born in Nigeria after an uncompli-
cated pregnancy. He did well during his first year and a half, but was noted to be pale at
a routine 18 month well-child check. At that time he had a hemoglobin (Hgb)c of7.0 g/dl
(normal range: 10.5 - 14.0), and a mean corpuscular volume (MCV) of 49 ,um3 (normal
range: 72 - 90). He had no history of blood loss or dietary insufficiency. Oral iron thera-
py was initiated with no response. Next, a full replacement dose ofintravenous iron dex-
tran was given.
Six weeks later, laboratory evaluation showed persistent anemia. In general, even
severe iron deficiency anemia will be markedly improved within that period oftime after
parenteral treatment. P.D., however, had Hgb 7.8 g/dl, MCV 50 ,um3, hematocrit (Hct)
27.2 percent (normal range: 34 - 42), reticulocytopenia, serum ferritin level of 87 pg/l
(normal range: 10 - 75), transferrin iron saturation of 5 ,ug/dl (normal range: 15 - 40) and
red cell count of 5.36 x 106/ml (normal range: 3.70 - 5.30 x 106). Hemoglobin elec-
trophoresis results were reported as normal. We were consulted for a second opinion.
The parents of P.D. are alive and well, and he has a healthy older male sibling. No
family members had microcytosis or significant anemia. On physical examination, P.D.
was well-developed and appeared to be well-nourished. His height and weight were
greater than 90th percentile. He had dry, deeply pigmented skin, and pallor visible in the
nailbeds and palmar creases. Auscultation revealed a flow murmur, but no evidence of
structural heart disease. He had no organomegaly, adenopathy or bony abnormalities. His
blood smear is shown in Figure 2.
In summary, this toddler presented as a well-appearing child with profound
hypochromic, microcytic anemia unresponsive to oral iron therapy, and partially respon-
sive to intravenous iron therapy. His anemia persisted after total body iron stores were
repleted. Red cell morphology is consistent with severe iron deficiency, but the RBC count
was surprisingly high. He appears to have defects in both intestinal iron transport, and red
cell iron utilization. No genetic pattern can be discerned, because there is insufficient data.
However, similar patients have been described previously by George Buchanan [41 and
Kip Hartman [5]; the inheritance in those patients appears to be autosomal recessive.
Figure 2. Blood smear from
...... 0;: _ - ......... ;^ patient P.D. This smear was
116 a t- 9 >alW!!!!1 obtained approximately three >0wdt......$;Y,:l01_E..........monthsafterrepletionofbody
iron stores with intravenous iron dextran. Significant
hypochromia, microcytosis, anisocytosis and poikylocyto-
sis are still evident.
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MICROCYTIC (mk) MICE HAVE A SIMILAR DEFECT
There is a striking similarity between these human patients, and mice with the micro-
cytosis (mk) mutation, as noted previously by Robin Bannerman [6]. Homozygous mk
mice have hypochromic, microcytic anemia with red cell morphology which is indistin-
guishable from that of the patient, P.D., and a RBC count which is elevated out of pro-
portion to their anemia [7]. These mice fail to respond to oral iron, and respond poorly to
intravenous iron. Bone marrow transplantation experiments demonstrate defects at the
level of intestinal absorption as well as bone marrow utilization [8]. We hypothesize that
the gene defective in mk mice encodes a key iron transport molecule. We have undertak-
en positional cloning to identify and characterize that protein. This approach has several
major advantages over biochemical studies of iron transport. First, the functional rele-
vance ofthe protein has been established by an experiment of nature. Second, we are not
limited by the seemingly insurmountable technical difficulties oftrying to purify a protein
for which no good assay has been devised.
GENETIC LOCALIZATION OF mk
In the past five years, technical advances have had great impact on mouse genetics.
Dinucleotide repeats ofup to 100 basepairs in length (generally with the structure (CA))
are distributed randomly throughout mammalian genomes. These repeats, termed simple
sequence length polymorphism markers or SSLPs, have a convenient property of low
grade genetic instability. That is to say, they tend to remain constant in length within
inbred mouse strains, but they often vary in length between mouse strains. As aresult, they
can be used as genetic markers. William Dietrich, Eric Lander, and their colleagues have
described over seven thousand SSLP markers, and determined their positions on a high
resolution genetic map ofthe mouse genome [9]. These markers form the framework upon
which more precise genetic maps can be constructed. Analysis ofthese markers is carried
out as shown schematically in Figure 3.
To localize the mk gene precisely, we set up a large backcross breeding experiment.
After nearly one hundred generations ofinbreeding, the mice carrying the mkmutation are
considered a distinct recombinant inbred strain, termed MK/ReJ. Homozygous male
allele A
CACACACACACACACA
GTGTGTGTGTGTGTGT
allele B
CACACACACACACACACACACACA
GTGTGTGTGTGTGTGTGTGTGTGT
Figure 3. Analysis of SSLP markers. The strategy for PCR-based analysis of simple sequence
length polymorphisms (SSLPs) is shown schematically. Arrows represent PCR primers flanking
dinucleotide (CA) repeats found in non-coding DNA. The diagram on the right represents an acry-
lamide gel, fractionating PCR products from the two alleles A and B.
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Figure 4. Genetic map ofmk region on mouse chromosome 15. A genetic map ofthe mk candi-
date region is shown, with distances indicated in centimorgans (cM). Numerical marker designa-
tions refer to Dl5Mit markers, as described in the text (e.g. 14 is D15Mitl4). No recombinations
have been observed between the mk phenotype and the candidate gene. Flanking markers define a
genetic interval of0.36 cM total; on average, this corresponds to about 700 kb.
mklmk mice from the MK/ReJ strain were mated (outcrossed) with female mice from
either of two strains which differ at most SSLP loci. The offspring from that cross (first
filial generation, or FI) derived 50 percent of their genetic makeup from the MK/ReJ
father, and 50 percent oftheir genetic makeup from the outcross mother. The Fl females
were then bred (backcrossed) to their MK/ReJ fathers. Meiotic recombinations were
apparent in the offspring from this cross, and could be used to map the location ofthe mk
gene, through correlation of phenotype (microcytic, hypochromic anemia) and SSLP
genotype at various loci. Using this strategy, we confirmed classic genetic mapping ofmk
to mouse chromosome 15, and determined a small region near the telomere which must
contain the mk gene.
At the time of the symposium, we had analyzed 551 backcross animals. These data
were used to generate a genetic map ofthe region surrounding mk, as shown in Figure 4.
The mkphenotype is flanked by two SSLP markers (Dl5Mit markers 14 and 77) towards
the centromere, and one SSLP marker (DlSMit 97) towards the telomere. The entire can-
didate region was less than 0.4 centimorgans. A fourth marker, derived from the 3'
untranslated region of a cDNA mapping to that region, was invariably linked to the phe-
notype, and showed no recombinations in the backcross panel. This was considered a
potential candidate gene. We now have strong data indicating that that cDNA from the
Nramp2 gene encodes the mk protein; those results will be published elsewhere.
Three genes known to map to mouse chromosome 15 encode proteins have features
which led us to consider them as candidates for mk. Two transcription factors that have
been shown tobeimportant forred blood cell development, p45 NF-E2 [10] and CP2 [11],
are encoded by genes residing on the portion of human chromosome 12q which is syn-
tenic with the mkregion ofmouse chromosome 15. Peters et al. previously suggested that
p45 NF-E2 was the mk gene [12], but this was later shown to be incorrect [13-15]. We
have also ruled out CP2, based on more precise mapping.
A third gene, encoding the protein Rab5b, also maps to this region. Rab5b is a cyto-
plasmic ras-like protein, which co-localizes with the transferrin receptor in an endosomal
compartment [16]. While this protein seemed like a plausible candidate for the mk gene
product, further map data have excluded that possibility.
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The ultimate proof of the identity of the mk gene will involve functional reconstitu-
tion of iron transport in cells carrying the mk defect. To that end, we have established
immortalized erythroid precursor cell lines from animals homozygous for the mk muta-
tion, and their heterozygous (unaffected) littermates. This was achieved by infecting dis-
aggregated fetal liver cells with a retrovirus carrying myc and rafoncogenes, as described
previously [17]. Five cell lines were obtained from mutant animals, and five cell lines
were obtained from unaffected animals. Preliminary studies have shown that these lines
can be induced to differentiate into more mature erythroid forms by treatment with ery-
thropoeitin. They express mRNAencoding alpha and betaglobin proteins. Cell lines from
mk homozygotes appear to make less ferritin mRNA than controls. We are in the process
ofdesigning a reliable assay for iron transport in these cells.
OTHER IRON DEFICIENT MOUSE STRAINS
In addition to mk, there are other mouse mutants which have defects in iron transport
pathways. Mice homozygous for the hemoglobin deficit (hbd) trait have increased serum
iron, but poor red cell iron utilization [18]. The hbd gene maps to a chromsomal position
distinct from that of mk, transferrin, ferritin, or the transferrin receptor. We are currently
analyzing a large backcross to precisely localize the hbd gene. Mice homozygous for the
flexed tail (f) mutation have fetal siderocytic anemia, apparently due to a prenatal defect
in red cell iron utilization [19]. We have just begun to map the f mutation.
Hypotransferrinemic (hpx) mice have a splicing defect which alters the mRNA encoding
transferrin, and consequently make little or no functional transferrin protein. These mice
have the surprising phenotype ofsevere iron deficiency anemia in the setting of systemic
iron overload. These mouse strains, and others, offer a greatdeal ofinformation about iron
transport.
CONCLUSIONS
The advent of high resolution chromosomal mapping in the mouse has greatly facil-
itated positional cloning efforts. We have taken advantage of this, to use a genetic
approach to work out the details of iron transport pathways. Several spontaneous mouse
mutants with defects in key transport steps have been characterized by mouse breeders.
Their observable phenotype is hypochromic, microcytic anemia, resulting from insuffi-
ciency of iron for hemoglobin production. We are studying several of the most informa-
tive of these mutants. Microcytic anemia (mk) mice have poor absorption ofdietary iron
through the intestine, and poor uptake of plasma iron by red cell precursors, indicating
both intestinal and hematopoietic cell defects. Hemoglobin deficit (hbd) mice have nor-
mal intestinal iron absorption, but defective red cell iron uptake. Flexed tail (f) mice have
an isolated defect in red cell iron utilization, that causes them to form abnormal iron gran-
ules in the cytoplasm of red cell precursors. We plan to clone and characterize each of
these defective genes. Ourlong term goal is to define all molecular steps in iron transport,
from the intestine to the site of hemoglobin synthesis in the erythron. The mutant mice
described above, and others yet to be studied, will be enormously instructive in this
endeavor. Once key proteins have been identified, biochemical and genetic interaction
studies should help identify other components ofthe pathways.
It is likely that iron transport mechanisms are similar among mammals, and that
lessons learned from mice will lead to an understanding ofhuman iron transport. A small
group of Hematology Clinic patients, followed at Children's Hospital, have clinical fea-
tures that are remarkably similar to the genetic iron transport disorders seen in mk, hbd
and other mouse mutants. We will soon be in aposition to test whetherthe human patients
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have mutations in genes homologous to those affected in the mice. In the long term, we
hope that improved understanding of iron transport will lead to novel therapies for iron
deficiency and iron overload disorders.
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